Otsuka and Lundbeck get FDA nod for schizophrenia, bipolar disorder injection
The FDA approved a new long-acting drug for schizophrenia and bipolar disorder on Thursday, adding to the growing rank of drugs for the mental disorders that don’t have to be taken as an oral daily treatment.
Otsuka and Lundbeck’s Abilify Asimtufii (aripiprazole) only needs to be injected once every two months. The FDA approved their NDA for the extended-release injectable as a treatment for schizophrenia and a maintenance therapy for adults with bipolar I.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.